Large cap
Tenneco's DaVinci suspension wins three more OEMs, order book covers FY28
A record 18.8% EBITDA margin in FY26 rests on the DaVinci DCX system, which is now expanding to multiple new customers. The ₹1,400 crore capex push is for factories to feed exports and upcoming regulations.
IndusInd Bank denies fresh whistleblower report sent to PMO and RBI
Shares fell over 2% on the news. The bank says the concerns are old, already examined, and that no regulator has been in touch.
Astral lines up 51 institutional desks for June 8 meet
The pipes-and-fittings maker will host one-on-one meetings with a concentrated group of high-conviction investors in Mumbai.
Suzlon plans quadruple sales by FY31, enters battery storage
The wind-turbine maker's five-year roadmap targets 10 GW in annual sales, a storage factory by 2027, and 40% of India's domestic wind market.
Piramal Pharma's Dahej plant clears its last environmental hurdle
The Gujarat Pollution Control Board has permanently revoked its closure directions. The risk of a surprise shutdown at a key manufacturing hub is gone.
Anand Rathi promoter sells ₹506 cr of stock, cuts stake by 1.74%
Anand Rathi Financial Services offloaded 14.46 lakh shares via open-market trades on May 29. The sale comes after recent pledge reorganisations by the same promoter entity.
NLC India investor transcript adds nothing new on FY26 results
A May 27 meeting with institutional investors rehashed Q4 numbers already disclosed. No new guidance or strategic shifts were revealed.
Narayana Hrudayalaya's Q4 transcript adds no new data
The full transcript of the May 26 earnings call is a procedural filing. It contains no new financial information or strategic shifts beyond the concall summary already in the market.
Suzlon delivered record turbines but missed its own market-share goal by half
Record 2,456 MW in FY26 deliveries drove a 54% revenue jump to ₹16,679 crore. The catch: management commissioned just 744 MW against a 1,500 MW market-share target.
Alkem undercuts pen injectors with India's first ₹350 semaglutide syringe
A single-shot format at a low price point is designed to widen access to a drug currently dominated by pricier delivery devices.
RVNL profit fell 43% last quarter. A ₹3,400 cr cash recovery changes the story.
One-off charges and low-margin legacy work hammered quarterly profit, but a major Ministry settlement clears a key cash hurdle for FY27.
Acme Solar puts a number on its raise. Floor price is ₹294.13.
The board approved a QIP in August. Now the floor is set and the book is open. The final discount and size will determine the dilution.
NMDC clears 53 mt in FY26, reopens two mines for the first time in 50 years
The miner beat its production target and is now doubling capex to restart Deposit 4 and Deposit 13, setting the stage for a push to 100 mt capacity by 2030.
Gujarat Energy profit drops 48% in first full year post-GSPC-GSPL merger
The restructured company's net profit fell to ₹1,677.58 crore, but the board still recommended a ₹8.90 per-share dividend.
Tata Technologies gets SAP sell rights across India and the US.
The authorization lets Tata Technologies sell SAP solutions directly, not just implement them, shifting its model from services to solutions.
Glenmark cuts FY27 margin guidance to 21-22%, delays Envafolimab launch
The mid-year guidance cut signals costs and headwinds are deeper than management initially forecast. The oncology launch is now out a year.
Godrej Properties lands 23.2-acre Greater Noida plot for ₹7,000 cr
The parcel has a revenue potential larger than the company's entire FY26 revenue, making it a material addition to the NCR pipeline.
Tenneco Clean Air India posts record 18.8% EBITDA margin in Q4
Tenneco Clean Air India reports a 19% jump in quarterly profit as value-added revenue climbed 17.5% year-on-year.
SEBI hits Suzlon with ₹28.95 crore penalty for legacy misstatements
Regulators overturned a previous discharge order regarding financial reporting from FY2013-18. The company plans to appeal.
Wockhardt's ZAYNICH wins FDA approval, first novel drug from an Indian pharma
The antibiotic beat meropenem in a 530-patient trial, validating a 15-year R&D pivot and opening a US market with 600,000+ annual hospitalisations.
Rubicon's profit doubled. Its factory is still a year away.
Q4 revenue jumped 44% to ₹514 cr, but reliance on outsourced manufacturing is squeezing gross margins. Pithampur commissioning is the fix.
IRCTC caps margin target at 30% as catering, tourism volumes grow
The ticketing cash cow is being diluted by mass-volume, lower-margin verticals. Management is accepting the trade-off.
Rubicon's profit grows twice as fast as its revenue
Net profit surged 83.6% on 36.6% revenue growth. A clean audit and a ₹1.50 dividend seal the year.
Physicswallah's latest shareholder letter adds no new financial data
The company's latest update provides management commentary on previously disclosed FY26 results, offering no material changes to its financial position.
Patanjali Foods faces a ₹1,352.9 cr tax demand from Tamil Nadu GST
The company received a show cause notice for FY23 alleging tax discrepancies. Management plans to contest the claim and expects no financial liability.